Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Empagliflozin tablets are used to treat type 2 diabetes. This medication is used along with diet and exercise to improve blood sugar control in people with type 2 diabetes. This product is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Recommended dose: The recommended dose of this product is 10 mg once a day in the morning, on an empty stomach or after eating. In patients who tolerate this product, the dose may be increased to 25 mg. In volume-depleted patients, it is recommended that the volume depletion be corrected before initiating use of this product. In patients with renal impairment, it is recommended to evaluate renal function before starting to use this product and periodically thereafter. Patients with eGFR lower than 45mL/min/1.73m2 should not use this product. No dose adjustment is required for patients with eGFR greater than or equal to 45mL/min/1.73m2. If eGFR continues to be lower than 45mL/min/1.73m2, this product should be discontinued. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. Empagliflozin exposure is increased in patients with severe hepatic impairment. There is limited experience in treating patients with severe hepatic impairment, and therefore, its use is not recommended for this population.

Drug contraindications:
Contraindicated if allergic to this product and disabled if renal function is impaired
Related dosage forms:
empagliflozin tablets